ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
ROCHESTER, Minn. /ScoopCloud/ -- yriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.
